GlassScriptPhysician profile
David R Williams
NPI 1275528895
$5,003.23
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $582 · 2021: $1,220 · 2022: $957 · 2023: $974 · 2024: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349 · Education: $14.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.99 |
| Education | $14.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $782.51 | 2020-2024 | Vraylar, Ubrelvy, Synthroid |
| Novo Nordisk INC | $675.17 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $385.69 | 2019-2024 | |
| Lilly USA, LLC | $355.37 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.97 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $227.05 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $224.28 | 2020-2023 | Belsomra, Gardasil 9, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.59 | 2019-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $178.32 | 2019-2023 | Xarelto |
| Dexcom, INC. | $163.74 | 2021-2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $156.20 | 2019-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $141.27 | 2019-2024 | Evusheld, Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $139.84 | 2019-2022 | |
| Glaxosmithkline, LLC. | $114.46 | 2020-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $113.35 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.